Business
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232
NEWARK, Calif., May 24, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first human subject has been dosed in a
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":" NEWARK, Calif., May 24, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232, a novel oral interleukin-23 receptor (IL-23R) antagonist peptide. This study is designed to determine the safety, tolerability, and pharmacokinetics of PN-232 in healthy volunteers. Recruitment for the study is ongoing. \n\"PN-232 is a second-generation, oral, IL-23 receptor antagonist candidate currently being developed in collaboration with Janssen Research & Development, LLC,\" said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. \"Today's announcement marks another step forward in our joint efforts to discover and develop novel oral treatment regimens for diseases that are moderated by intervention on the IL-23 pathway. Our joint efforts have now led to three different oral IL-23 antagonists: PTG-200, PN-235, and PN-232.\" \nThis Phase 1 study is designed to determine the safety, tolerability, and pharmacokinetics of PN-232 in healthy volunteers. It is a first-in-human study for PN-232 that will be conducted in three parts. Part 1 is a single ascending dose study, Part 2 is multiple ascending dose study, and Part 3 is crossover solid dose comparison and effect-of-food study. More complete information on the study is available at https://clinicaltrials.gov/ct2/show/NCT04819620.\nProtagonist and Janssen Biotech, Inc., have a research, co-development and commercialization agreement for IL-23 receptor targeted therapeutics with applications in various disease areas. According to the agreement, Janssen will be responsible for development and commercialization activities of compound candidates beyond Phase 2. Protagonist is eligible to receive research, development, regulatory and sales milestone payments and has an option to co-detail products in the U.S. market.\nAbout Protagonist TherapeuticsProtagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform.\nProtagonist-developed compounds currently include rusfertide (PTG-300), an investigational, injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 cli...